Search | Clinical Trials Finder

Conditions: Breast Cancer
Interventions: PF-07220060, letrozole, abemaciclib, palbociclib, ribociclib; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 1,035 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2037
U.S. locations: 218
States / cities: Birmingham, Alabama • Chandler, Arizona • Gilbert, Arizona + 135 more

Conditions: Breast Cancer
Interventions: Letrozole; Drug
Lead sponsor: Roxane Laboratories; Industry
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: HR+ Breast Cancer, Triple Negative Breast Cancer (TNBC), CCNE1 Amplified Advanced Solid Tumors, HR+ HER2- Breast Cancer
Interventions: NKT5097 CDK2/CDK4 dual degrader, Fulvestrant, Letrozole; Drug
Lead sponsor: NiKang Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 361 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 18
States / cities: Duarte, California • La Jolla, California • Denver, Colorado + 15 more

Conditions: Breast Cancer, Breast Neoplasm
Interventions: Pazopanib; Drug
Lead sponsor: Hope Rugo, MD; Other
Eligibility: 18 Years and older · Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Breast Cancer Metastatic
Interventions: Amcenestrant, Fulvestrant, Anastrozole, Letrozole, Exemestane, Tamoxifen; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 367 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 14
States / cities: Birmingham, Alabama • Bakersfield, California • Santa Monica, California + 11 more

Conditions: Hormone Receptor Positive Breast Cancer
Interventions: Everolimus, Letrozole, Exemestane, Alcohol-free dexamethasone mouth rinse (Stomatitis sub-study), Standard of care to treat stomatitis (Stomatitis sub-study); Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 202 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2021
U.S. locations: 15
States / cities: Birmingham, Alabama • Gilbert, Arizona • Loma Linda, California + 12 more

Conditions: HER2 Negative Breast Cancer
Interventions: Ribociclib 400mg, Letrozole 2.5mg, Anastrazole 1mg, Goserelin 3.6 MG, Adjuvant chemotherapy; Drug · Radiation
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Metastatic Breast Cancer
Interventions: Inavolisib, Phesgo, Placebo, Taxane-based Chemotherapy, Optional Endocrine Therapy of Investigator's Choice; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 230 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2032
U.S. locations: 20
States / cities: Gilbert, Arizona • Burbank, California • Corona, California + 17 more

Conditions: Breast Cancer
Interventions: Vepdegestrant (ARV-471/PF-07850327), Palbociclib, Letrozole; Drug · Combination Product
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 3
States / cities: Plantation, Florida • Norfolk, Virginia

Conditions: Breast Cancer
Interventions: PF-07220060, letrozole; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 10
States / cities: Barrington, Illinois • Crystal Lake, Illinois • Park Ridge, Illinois + 2 more

Conditions: Metastatic Breast Cancer
Interventions: Dasatinib, Letrozole; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 27
States / cities: Sedona, Arizona • Tucson, Arizona • Denver, Colorado + 22 more

Conditions: Breast Cancer
Interventions: Everolimus, Exemestane, Everolimus Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 724 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 63
States / cities: Chandler, Arizona • Fayetteville, Arkansas • Anaheim, California + 54 more

Conditions: Hormone Receptor Positive HER-2 Negative Breast Cancer, Metastatic Breast Cancer, Recurrent Breast Cancer
Interventions: Alisertib, Endocrine therapy; Drug
Lead sponsor: Puma Biotechnology, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 225 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 35
States / cities: Birmingham, Alabama • Phoenix, Arizona • Beverly Hills, California + 28 more

Conditions: Endometrial Cancer
Interventions: Metformin, Letrozole, Everolimus; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2026
U.S. locations: 6
States / cities: Pensacola, Florida • Voorhees Township, New Jersey • Houston, Texas

Conditions: Breast Cancer, Breast Carcinoma, Breast Tumors
Interventions: Letrozole, palbociclib; Drug
Lead sponsor: NSABP Foundation Inc; Network
Eligibility: 18 Years and older · Female only
Enrollment: 307 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 19
States / cities: Long Beach, California • Miami, Florida • Decatur, Illinois + 13 more

Conditions: Polycystic Ovary Syndrome, PCOS, Infertility
Interventions: Letrozole, Clomiphene Citrate; Drug
Lead sponsor: Rachel Mejia; Other
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 190 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 4
States / cities: Davenport, Iowa • Iowa City, Iowa • West Des Moines, Iowa + 1 more

Conditions: Breast Cancer
Interventions: BMS-690514, Lapatinib, Letrozole; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 4
States / cities: Abilene, Texas • Beaumont, Texas • Fort Worth, Texas + 1 more

Conditions: Breast Cancer
Interventions: letrozole; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 50 Years and older · Female only
Enrollment: 261 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 48
States / cities: Huntsville, Alabama • Little Rock, Arkansas • Grass Valley, California + 43 more

Conditions: Advanced Metastatic Breast Cancer
Interventions: Ribociclib, Tamoxifen, Letrozole, Anastrozole, Goserelin, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 59 Years · Female only
Enrollment: 672 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2023
U.S. locations: 35
States / cities: Bakersfield, California • Los Angeles, California • Denver, Colorado + 29 more

Conditions: Breast Cancer
Interventions: XL147 (SAR245408), XL765 (SAR245409), letrozole (Femara); Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 11
States / cities: Los Angeles, California • Denver, Colorado • Fort Meyers, Florida + 8 more

Conditions: Healthy
Interventions: Letrozole Tablets 2.5 mg, Femara® Tablets 2.5 mg; Drug
Lead sponsor: Mylan Pharmaceuticals Inc; Industry
Eligibility: 40 Years and older · Female only
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Breast Cancer
Interventions: BMS-754807, letrozole; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 21
States / cities: Birmingham, Alabama • Scottsdale, Arizona • San Diego, California + 14 more

Conditions: Breast Cancer
Interventions: Amcenestrant (SAR439859), Letrozole; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 6
States / cities: Tucson, Arizona • Los Angeles, California • Fort Wayne, Indiana + 3 more

Conditions: Breast Cancer
Interventions: Letrozole, Placebo, Taselisib; Drug · Other
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 334 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 8
States / cities: Santa Ana, California • Boston, Massachusetts • Basking Ridge, New Jersey + 5 more

Search by objective public record fields.

Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease

Bioequivalency Study of Letrozole 2.5 mg Tablets Under Fasted Conditions

A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors

Reversing Hormone Resistance in Advanced Breast Cancer With Pazopanib

Phase 2 Study of Amcenestrant (SAR439859) Versus Physician's Choice in Locally Advanced or Metastatic ER-positive Breast Cancer

Open-label, Phase II, Study of Everolimus Plus Letrozole in Postmenopausal Women With ER+, HER2- Metastatic or Locally Advanced Breast Cancer

Impact of Omitting Chemo Based on Patient's Selection for ER-Positive, HER2-Negative Breast Cancer With Ribociclib and Endocrine Therapy

A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer

Vepdegestrant (ARV-471/PF-07850327) + Palbociclib vs Letrozole + Palbociclib in ER(+)/HER2(-) Advanced Breast Cancer

A Study to Learn About the Study Medicine PF-07220060 Together With Letrozole Compared to Letrozole Alone in Women Post Menopause

Randomized Phase II Trial of Letrozole With or Without Dasatinib as First and Second-line Treatment for Hormone Receptor-positive, HER2-negative Post-menopausal Breast Cancer That is Unresectable, Locally Recurrent or Metastatic

Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole

A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer

A Phase II, Single-Arm Study of RAD001 (Everolimus), Letrozole, and Metformin in Patients With Advanced or Recurrent Endometrial Carcinoma

A Phase II Randomized Study Evaluating the Biological and Clinical Effects of the Combination of Palbociclib With Letrozole as Neoadjuvant Therapy in Post-Menopausal Women With Estrogen-Receptor Positive Primary Breast Cancer

Randomized Controlled Trial of Combined Letrozole and Clomid (CLC II) Versus Letrozole Alone for Women With Anovulation

Efficacy and Safety of BMS-690514 in Combination With Letrozole to Treat Metastatic Breast Cancer

Rheumatological Evaluation of Anastrozole and Letrozole as Adjuvant Treatment in Post-menopausal Women With Breast Cancer

Study of Efficacy and Safety in Premenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer

Study of XL147 (SAR245408) or XL765 (SAR245409) in Combination With Letrozole in Subjects With Breast Cancer

Fasting Study of Letrozole Tablets 2.5 mg and Femara® Tablets 2.5 mg

Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Patients With Hormone Receptor-Positive Breast Cancer and Resistance to Non-Steroidal Aromatase Inhibitors

Phase 2 Window Study of SAR439859 (Amcenestrant) Versus Letrozole in Post-menopausal Patients With ER+, HER2- Pre-operative Post-menopausal Primary Breast Cancer

A Study of Neoadjuvant Letrozole + Taselisib Versus Letrozole + Placebo in Post-Menopausal Women With Breast Cancer (LORELEI)